High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-1864
Abstract: Purpose: p95HER2 is a truncated form of HER2 that confers resistance to trastuzumab in vitro, but clinical results have been conflicting to date. Given that p95HER2 levels correlate with total HER2 expression levels, which confer… read more here.
Keywords: p95her2; her2 ratio; cancer; p95her2 her2 ... See more keywords
Abstract PS8-04: Targeting clinically advanced breast cancer with conjugated and unconjugated HER2 antibodies: Does copy number matter?
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-ps8-04
Abstract: Background: HER2-targeted therapy is broadly used in advanced breast cancer (aBC). For HER2+ aBC (HER2 IHC 3+ or 2+/ISH+), 1L standard of care includes unconjugated HER2 antibodies trastuzumab and pertuzumab (HP) in combination with chemotherapy.… read more here.
Keywords: cancer; breast; her2 ratio; her2 ... See more keywords